Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019

NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that...
August 12, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019

SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...
August 09, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019

NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
August 08, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results

TYME Presented Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic CancerNYU Langone and TYME Entered...
August 07, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer

SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...
August 01, 2019 08:00 ET | Source: Tyme Technologies, Inc.

Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management...
July 29, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Technologies Announces New Collaboration with NYU Langone to Advance TYME’s Cancer Metabolism-Based Therapy, SM-88

NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company, announced a new research collaboration with NYU Langone Health to advance the...
July 08, 2019 08:00 ET | Source: Tyme Technologies, Inc.

REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS)....
July 05, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer

In this poor prognosis population, SM-88 demonstrated median overall survival (OS) of 6.4 months as of April 25, 2019 Efficacy indicators showed strong correlation with greater overall survival (OS)....
June 07, 2019 08:00 ET | Source: Tyme Technologies, Inc.

TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019

SM-88 (racemetyrosine) is an oral, investigational cancer metabolism-based therapy that has demonstrated responses across 15 different cancersNew oral approach aimed at disrupting cancer metabolism in...